Loading...

Grace Liang

Title(s)Associate Physician, Neurosciences
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #0662
La Jolla CA 92093
Phone000-000-NULL
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A long-term, open-label study of valbenazine for tardive dyskinesia. CNS Spectr. 2020 May 18; 1-9. Lindenmayer JP, Verghese C, Marder SR, Burke J, Jimenez R, Siegert S, Liang GS, O'Brien CF. PMID: 32419679.
      View in: PubMed   Mentions:    Fields:    
    2. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia. J Clin Psychopharmacol. 2019 Nov/Dec; 39(6):620-627. Marder SR, Singer C, Lindenmayer JP, Tanner CM, Comella CL, Verghese C, Jimenez R, Liang GS, Burke J, O'Brien CF. PMID: 31688452.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. Mov Disord. 2019 08; 34(8):1203-1209. Stacy M, Sajatovic M, Kane JM, Cutler AJ, Liang GS, O'Brien CF, Correll CU. PMID: 31234240.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study. J Clin Psychiatry. 2018 12 18; 80(1). Correll CU, Cutler AJ, Kane JM, McEvoy JP, Liang GS, O'Brien CF. PMID: 30695293.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials. Drug Saf. 2018 04; 41(4):429-440. Thai-Cuarto D, O'Brien CF, Jimenez R, Liang GS, Burke J. PMID: 29218680.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    6. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. J Clin Psychiatry. 2017 Nov/Dec; 78(9):1344-1350. Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, Liang GS, O'Brien CF. PMID: 29141124.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    7. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Psychopharmacol Bull. 2017 08 01; 47(3):53-60. Correll CU, Josiassen RC, Liang GS, Burke J, O'Brien CF. PMID: 28839340.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. Psychopharmacol Bull. 2017 08 01; 47(3):61-68. Josiassen RC, Kane JM, Liang GS, Burke J, O'Brien CF. PMID: 28839341.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    9. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Psychopharmacol Bull. 2017 08 01; 47(3):69-76. Kane JM, Correll CU, Liang GS, Burke J, O'Brien CF. PMID: 28839342.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci. 2017 Jun 15; 377:137-143. Chou KL, Elm JJ, Wielinski CL, Simon DK, Aminoff MJ, Christine CW, Liang GS, Hauser RA, Sudarsky L, Umeh CC, Voss T, Juncos J, Fang JY, Boyd JT, Bodis-Wollner I, Mari Z, Morgan JC, Wills AM, Lee SL, Parashos SA. PMID: 28477684.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    11. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017 05 01; 174(5):476-484. Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF. PMID: 28320223.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    12. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. J Neurol Sci. 2017 Feb 15; 373:116-123. Tetrud J, Nausieda P, Kreitzman D, Liang GS, Nieves A, Duker AP, Hauser RA, Farbman ES, Ellenbogen A, Hsu A, Kell S, Khanna S, Rubens R, Gupta S. PMID: 28131167.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    13. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93. Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM. PMID: 25668262.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    14. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014 Dec; 20(12):1335-40. Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, Dillmann U, Rubens R, Kell S, Gupta S. PMID: 25306200.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    15. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol. 2014 Jun; 71(6):710-6. Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM. PMID: 24711047.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    16. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol. 2009 Sep; 66(9):1099-104. Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM. PMID: 19597081.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    17. Subthalamic nucleus deep brain stimulation for severe idiopathic dystonia: impact on severity, neuropsychological status, and quality of life. J Neurosurg. 2007 Jul; 107(1):29-36. Kleiner-Fisman G, Liang GS, Moberg PJ, Ruocco AC, Hurtig HI, Baltuch GH, Jaggi JL, Stern MB. PMID: 17639870.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    18. Long-term outcomes of bilateral subthalamic nucleus stimulation in patients with advanced Parkinson's disease. Stereotact Funct Neurosurg. 2006; 84(5-6):221-7. Liang GS, Chou KL, Baltuch GH, Jaggi JL, Loveland-Jones C, Leng L, Maccarone H, Hurtig HI, Colcher A, Stern MB, Kleiner-Fisman G, Simuni T, Siderowf AD. PMID: 17063043.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    19. Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's disease. Mov Disord. 2006 Jun; 21(6):746-53. Siderowf A, Jaggi JL, Xie SX, Loveland-Jones C, Leng L, Hurtig H, Colcher A, Stern M, Chou KL, Liang G, Maccarone H, Simuni T, Baltuch G. PMID: 16463342.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    20. Severe neuropathy with leaky connexin32 hemichannels. Ann Neurol. 2005 May; 57(5):749-54. Liang GS, de Miguel M, Gómez-Hernández JM, Glass JD, Scherer SS, Mintz M, Barrio LC, Fischbeck KH. PMID: 15852376.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    21. Unilateral battery depletion in Parkinson's disease patients treated with bilateral subthalamic nucleus deep brain stimulation may require urgent surgical replacement. Stereotact Funct Neurosurg. 2004; 82(4):153-5. Chou KL, Siderowf AD, Jaggi JL, Liang GS, Baltuch GH. PMID: 15475657.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    Grace's Networks
    Concepts (111)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (5)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑